Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Neurotech SA

This article was originally published in Start Up

Executive Summary

Neurotech is making use of the angiogenic properties of tumors to eradicate them. Beyond brain tumors, Neurotech is targeting other conditions where angiogenesis is important, for example, ischemic stroke. Neuortech's approach is also suited to a variety of other neurological disorders, including Alzheimer's disease and Parkinson's disease.

Related Content

Planet Neuron: Start-Ups in Neurobiology


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts